Copper-associated hepatopathy (CuAH), also referred to as copper storage disease, is a well-recognized liver disorder in dogs resulting from excessive copper accumulation within the liver’s cells (hepatocytes). Though the two terms are used interchangeably in both clinical and everyday settings, they reflect different drivers – copper storage disease more precisely describes the primary inherited form caused by genetic defects in copper metabolism, while CuAH encompasses any dog with pathological copper accumulation, regardless of cause.

This pathological buildup triggers oxidative stress and inflammation, and may progressively lead to chronic hepatitis, hepatic failure, or death if left untreated. While certain breeds are genetically predisposed due to defects in copper metabolism, current evidence shows that any breed or mixed-breed dog can be affected.

Normally, copper – a trace dietary element essential for enzymatic functions – is regulated and excreted by the liver. However, factors such as environmental exposures and dietary changes, especially rising copper content in commercial dog food, have resulted in more cases across a broader range of breeds and ages.

Critically, some dogs accumulate toxic copper concentrations with no symptoms at all and normal liver enzyme levels, making early awareness and routine monitoring essential. When symptoms do appear, they are often vague, and emerge only once the disease is already advanced.

Diagnosis relies on liver biopsy, which confirms copper accumulation and guides treatment. Management typically involves dietary copper restriction and medications that help remove excess copper from the body, strategies developed from the latest veterinary consensus and research.

Certain breeds have a documented genetic predisposition to copper‑associated hepatopathy, including Bedlington Terriers, Labrador Retrievers, Doberman Pinschers, West Highland White Terriers, Dalmatians, Skye Terriers, and Cocker Spaniels.

These predispositions are linked to variants in genes that regulate copper transport and storage, most notably COMMD1 in Bedlington Terriers and ATP7B, ATP7A, and RETN in Labrador Retrievers, with ongoing work exploring additional modifiers in Labradors and other breeds. While these breeds remain at higher genetic risk, biopsy and genetic studies now confirm clinically important copper accumulation in many other purebred and mixed‑breed dogs, often driven or worsened by dietary factors.

Even with expanded DNA panels, copper-related results should be viewed as risk modifiers, not guarantees: dogs with “clear” ATP7B/ATP7A/RETN status can still develop clinically important copper accumulation from diet and other factors, and some dogs carrying risk variants will never become sick.

Recent studies by veterinary institutions and the American College of Veterinary Internal Medicine (ACVIM) show a sharp increase in copper-associated hepatopathy across all breeds and mixes. Contributing factors include modern diet formulations with highly bioavailable copper, the absence of an upper dietary copper limit in U.S. regulations, and the widespread shift to inorganic copper chelates, forms shown to be more readily absorbed by the liver than the copper proteinate forms used historically.

Genetics remain important, but the rise in cases, combined with better diagnostic awareness and more frequent liver biopsies, means this disease is no longer confined to traditionally at-risk breeds. Strikingly, wild coyotes sampled as natural controls showed median hepatic copper concentrations roughly ten times lower than those found in commercial-fed domestic dogs, pointing directly at diet as a primary driver.

Veterinary experts now recognize that copper-associated hepatopathy is multifactorial, involving a complex interplay of genetic, nutritional, physiologic, and environmental factors that can cause copper buildup and liver injury in any dog.

Optimal care for copper‑associated hepatopathy is a team effort. Most dogs do best under the shared guidance of a primary care veterinarian, a board‑certified internal medicine specialist (DACVIM), and, when possible, a board‑certified veterinary nutritionist (DACVN).

Internal medicine specialists coordinate advanced diagnostics such as abdominal ultrasound and liver biopsy, working with a pathologist experienced in hepatic disease to assess copper distribution, inflammation, and fibrosis. Biopsy samples are also submitted for quantitative copper analysis, which confirms the diagnosis and helps stage disease severity.

Veterinary nutritionists then use those biopsy results and bloodwork to design individualized, copper‑restricted diets and long‑term nutrition plans, while clinicians adjust medications (chelation, zinc, antioxidants, and liver‑supportive drugs) over time based on repeat labs and clinical response.

Treatment usually combines chelation therapy, copper‑restricted diets, and antioxidant liver support. Chelators (such as D‑penicillamine or trientine, when indicated) help remove excess copper already stored in the liver, while carefully formulated low‑copper therapeutic diets and controlled treats are used to prevent it from building back up. Zinc and antioxidants (for example vitamin E, SAMe) are often added to reduce oxidative damage and support hepatocyte recovery.

Long‑term success depends on early diagnosis, adherence to the prescribed diet, regular bloodwork and imaging, and close collaboration with a veterinary team experienced in managing copper‑associated liver disease.

With early detection, appropriate copper reduction, and strict adherence to dietary and medical recommendations, many dogs experience stabilization of liver values and even partial reversal of inflammatory changes, maintaining a good quality of life for many years. Prognosis is generally most favourable when copper is reduced before advanced fibrosis or cirrhosis develops and when owners can reliably follow long‑term diet and monitoring plans.

However, delayed diagnosis, inconsistent treatment, or use of diets inappropriate for copper‑associated disease can allow progressive scarring (fibrosis) and portal hypertension to develop, at which point options become limited and the risk of liver failure and reduced survival time increases significantly.

Establish care with veterinary professionals who routinely manage liver disease so your dog’s plan is tailored to their biopsy results, bloodwork, imaging, and clinical signs. Ideally, your core team includes:

• Board‑certified veterinary internal medicine specialist (DACVIM) – interprets liver biopsy and imaging, stages disease, and manages medications such as chelators, zinc, and hepatoprotectants

• Board‑certified veterinary nutritionist (DACVN) – formulates and adjusts a copper‑restricted diet and treat plan that fits your dog’s other health needs and lifestyle.

After the initial stabilization phase, most dogs need re‑checks every 3–6 months, including liver enzymes and, when indicated, imaging or repeat bile acids, so treatment and diet can be fine‑tuned over time.